The Effect of Plasma Osmolality on Brain Glutamate



Status:Completed
Conditions:Schizophrenia
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:21 - 45
Updated:4/21/2016
Start Date:March 2007
End Date:March 2012

Use our guide to learn which trials are right for you!

The Role of Cortical Glutamate and GABA in Brains Osmotic Regulation: A Pilot Study in Healthy Volunteers and in Patients With Schizophrenia

This study is designed to test the hypothesis that plasma osmolality is linked with cortical
glutamate concentrations in the brain. It also investigates whether the glutamate response
in schizophrenia is enhanced compared to healthy controls.


Inclusion criteria for healthy controls

1. Ages of 21-45 years from all ethnic backgrounds.

2. Male or female.

3. Written informed consent.

4. Female subjects will be studied during the follicular phase of their menstrual
cycle.*

Exclusion criteria for healthy controls

1. DSM-IV diagnosis of psychotic, anxiety, mood disorder.

2. A history of significant medical/neurological disease. Unstable medical condition
based on EKG, vital signs, physical examination and laboratory work-up (CBC with
differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test, folic acid, B12
levels).

3. History of allergies to drugs such as sulfa, multiple adverse drug reactions or known
allergy to furosemide.

4. Any medication that in the opinion of the PI could interfere with either the safety
of the study and/or the outcome measures, such as over the counter cough suppressants
or antihistamines.

5. History of major psychiatric disorder in first-degree relatives.

6. Current substance abuse/dependency determined by plasma and urine toxicology.

7. Current treatment with medications with psychotropic effects.

8. Current pregnancy, unsatisfactory birth control method report for females.

9. Education < 12th grade.

10. Non-English speaking.

Inclusion criteria for patients with schizophrenia

1. Ages of 21-45 years from all ethnic backgrounds.

2. Male or female.

3. Written informed consent.

4. DSM-IV diagnosis of schizophrenia or schizoaffective disorder.

5. For treated patients: The patient has been on a stable dose of medications
(antipsychotics, antidepressants) for the past month and does not require a change of
medications or dose adjustment at study entry.

6. For untreated patients: Has refused to be treated with medications, maintains regular
clinic appointments with the clinicians, and does not pose an imminent danger to
himself or others.

7. Female subjects will be studied during the follicular phase of their menstrual
cycle*.

Exclusion criteria for patients with schizophrenia

1. A history of significant medical/neurological disease. Unstable medical condition
based on EKG, vital signs, physical examination and laboratory work-up (CBC with
differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test, folic acid, B12
levels).

2. Orthostatic systolic blood pressure change>20 mmHg or orthostatic pulse change>20
bpm.

3. History of polydipsia/hyponatremia**.

4. History of allergies to drugs such as sulfa, multiple adverse drug reactions or known
allergy to furosemide.

5. Any medication that in the opinion of the PI could interfere with either the safety
of the study and/or the outcome measures, such as over the counter cough suppressants
or antihistamines.

6. Current use of lithium (lithium directly interferes with electrolyte balance).

7. Currently on clozapine as clozapine may interfere with brain water regulation
(Leadbetter and Shutty, 1994).

8. Current substance abuse/dependency determined by plasma and urine toxicology.

9. Current treatment with benzodiazepines or mood stabilizers (these medications can
alter glutamate transmission).

10. Current pregnancy, unsatisfactory birth control method report for females.

11. IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.

12. Non-English speaking
We found this trial at
1
site
New Haven, Connecticut 06519
?
mi
from
New Haven, CT
Click here to add this to my saved trials